跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 47 条关于
“H3.1”
全部
47
临床试验
22
药物
9
机构
0
资讯
16
去年
Volition's Nu.Q H3.1 Biomarker Shows Promise for Sepsis Assessment in Large ICU Study
9个月前
VolitionRx's Sepsis Biomarker Selected for €6.3 Million French National Healthcare Initiative
4个月前
BIOMEDE Trial Reveals Biomarker-Driven Strategy for Pediatric Brain Cancer Despite Missing Primary Endpoint
11个月前
Esperion Therapeutics Stock Surges 13.1% Following Patent Settlement Victory with Dr. Reddy's
上个月
Obinutuzumab Beta Posts 93.1% Relapse Reduction in AQP4+ NMOSD, Joining a Crowded Efficacy Plateau
去年
U.S. Monoclonal Antibodies Market Projected to Reach $284.9 Billion by 2034, Growing at 13.1% CAGR
9个月前
Enveric Biosciences Raises $3.1 Million Through Warrant Exercise to Advance Neuroplastogenic Therapeutics
9个月前
Ascentage Pharma's Olverembatinib Shows 23.1% Response Rate in Rare GIST Subtype with Novel Lipid Metabolism Mechanism
3个月前
Obinutuzumab β (MIL62) Shows 93.1% Relapse Risk Reduction in Phase 3 Trial for AQP4-IgG+ NMOSD
3年前
U.S. Tuberous Sclerosis Drug Market Projected to Reach $1.25 Billion by 2030, Growing at 23.1% CAGR
第 1 页,共 2 页
上一页
下一页